https://www.selleckchem.com/products/itf3756.html
To determine which demographic and clinical characteristics are predictive of vision-related quality of life (VrQoL) and quality of life (QoL) in patients with macular oedema receiving intravitreal anti-vascular endothelial growth factor (VEGF) treatment. Vision-related quality of life (VrQoL) and quality of life (QoL) were measured in 712 patients with retinal exudative disease receiving anti-VEGF treatment at baseline, 6 and 12months. VrQoL was measured using an item-response theory based 47-question item bank (EyeQ), whereas QoL was
Like
Comment
Share
